Insider · CIK 0001391045
Legault Pierre
Reports to the SEC for 11 companies · NEW YORK, NY
Transactions
50
Companies
11
Filings
9
CIK
0001391045
Forms 4 and 5
Insider transactions
| Date | Company | Value |
|---|---|---|
| 2026-02-04 | SNDXSyndax Pharmaceuticals IncA Award | — |
| 2025-02-05 | SNDXSyndax Pharmaceuticals IncA Award | — |
| 2025-01-02 | BCYCBICYCLE THERAPEUTICS PLCA Award | — |
| 2025-01-02 | BCYCBICYCLE THERAPEUTICS PLC · Stock Option (right to buy)A Award | — |
| 2024-02-07 | SNDXSyndax Pharmaceuticals IncA Award | — |
| 2024-01-02 | BCYCBICYCLE THERAPEUTICS PLC · Stock Option (right to buy)A Award | — |
| 2024-01-02 | BCYCBICYCLE THERAPEUTICS PLCA Award | — |
| 2023-02-02 | SNDXSyndax Pharmaceuticals IncA Award | — |
| 2023-01-13 | SNDXSyndax Pharmaceuticals IncM Exercise/Conversion | +$136K |
| 2023-01-13 | SNDXSyndax Pharmaceuticals IncM Exercise/Conversion | +$67.9K |
| 2023-01-13 | SNDXSyndax Pharmaceuticals Inc · Stock Options (Right to buy)M Exercise/Conversion | — |
| 2023-01-13 | SNDXSyndax Pharmaceuticals Inc · Stock Options (Right to buy)M Exercise/Conversion | — |
| 2023-01-13 | SNDXSyndax Pharmaceuticals IncS Sale | −$135K |
| 2023-01-13 | SNDXSyndax Pharmaceuticals IncS Sale | −$270K |
| 2023-01-12 | SNDXSyndax Pharmaceuticals IncM Exercise/Conversion | +$227K |
| 2023-01-12 | SNDXSyndax Pharmaceuticals IncS Sale | −$642K |
| 2023-01-12 | SNDXSyndax Pharmaceuticals Inc · Stock Options (Right to buy)M Exercise/Conversion | — |
| 2023-01-03 | BCYCBICYCLE THERAPEUTICS PLC · Stock Option (right to buy)A Award | — |
| 2023-01-03 | BCYCBICYCLE THERAPEUTICS PLCA Award | — |
| 2022-08-05 | SNDXSyndax Pharmaceuticals IncS Sale | −$322K |
| 2022-08-05 | SNDXSyndax Pharmaceuticals IncM Exercise/Conversion | +$125K |
| 2022-08-05 | SNDXSyndax Pharmaceuticals IncS Sale | −$230K |
| 2022-08-05 | SNDXSyndax Pharmaceuticals IncM Exercise/Conversion | +$96.3K |
| 2022-08-05 | SNDXSyndax Pharmaceuticals Inc · Stock Options (Right to buy)M Exercise/Conversion | — |
| 2022-08-05 | SNDXSyndax Pharmaceuticals Inc · Stock Options (Right to buy)M Exercise/Conversion | — |
| 2022-02-02 | SNDXSyndax Pharmaceuticals IncA Award | — |
| 2022-01-03 | BCYCBICYCLE THERAPEUTICS PLC · Stock Option (right to buy)A Award | — |
| 2022-01-03 | BCYCBICYCLE THERAPEUTICS PLCA Award | — |
| 2021-12-22 | BCYCBICYCLE THERAPEUTICS PLCM Exercise/Conversion | +$830K |
| 2021-12-22 | BCYCBICYCLE THERAPEUTICS PLC · Stock Option (Right to Buy)M Exercise/Conversion | — |
| 2021-12-22 | BCYCBICYCLE THERAPEUTICS PLCS Sale | −$5.68M |
| 2021-12-22 | SNDXSyndax Pharmaceuticals IncS Sale | −$528K |
| 2021-12-22 | SNDXSyndax Pharmaceuticals IncM Exercise/Conversion | +$189K |
| 2021-12-22 | SNDXSyndax Pharmaceuticals Inc · Stock Options (Right to buy)M Exercise/Conversion | — |
| 2021-12-21 | BCYCBICYCLE THERAPEUTICS PLC · Stock Option (Right to Buy)M Exercise/Conversion | — |
| 2021-12-21 | BCYCBICYCLE THERAPEUTICS PLCS Sale | −$2.54M |
| 2021-12-21 | BCYCBICYCLE THERAPEUTICS PLCM Exercise/Conversion | +$376K |
| 2021-12-20 | BCYCBICYCLE THERAPEUTICS PLCS Sale | −$434K |
| 2021-12-20 | SNDXSyndax Pharmaceuticals IncS Sale | −$420K |
| 2021-12-20 | BCYCBICYCLE THERAPEUTICS PLCM Exercise/Conversion | +$63.9K |
| 2021-12-20 | SNDXSyndax Pharmaceuticals Inc · Stock Options (Right to buy)M Exercise/Conversion | — |
| 2021-12-20 | BCYCBICYCLE THERAPEUTICS PLC · Stock Option (Right to Buy)M Exercise/Conversion | — |
| 2021-12-20 | SNDXSyndax Pharmaceuticals IncM Exercise/Conversion | +$142K |
| 2021-04-08 | BCYCBICYCLE THERAPEUTICS PLC · Stock Option (Right to Buy)M Exercise/Conversion | — |
| 2021-04-08 | BCYCBICYCLE THERAPEUTICS PLCS Sale | −$7,679.07 |
| 2021-04-08 | BCYCBICYCLE THERAPEUTICS PLCS Sale | −$380K |
| 2021-04-08 | BCYCBICYCLE THERAPEUTICS PLCS Sale | −$400K |
| 2021-04-08 | BCYCBICYCLE THERAPEUTICS PLCM Exercise/Conversion | +$217K |
| 2021-04-05 | BCYCBICYCLE THERAPEUTICS PLC · Stock Option (Right to Buy)M Exercise/Conversion | — |
| 2021-04-05 | BCYCBICYCLE THERAPEUTICS PLCS Sale | −$5,033.34 |
Recent filings
- 4Legault Pierre0001193125-26-041167SEC(opens sec.gov)
- 4Legault Pierre0000950170-25-016346SEC(opens sec.gov)
- 4Legault Pierre0001415889-25-000929SEC(opens sec.gov)
- 4Legault Pierre0001562180-24-001214SEC(opens sec.gov)
- 4Legault Pierre0001209191-24-000889SEC(opens sec.gov)
- 4Legault Pierre0001562180-23-000944SEC(opens sec.gov)
- 4Legault Pierre0001562180-23-000413SEC(opens sec.gov)
- 4Legault Pierre0001209191-23-002176SEC(opens sec.gov)
- 4Legault Pierre0001562180-22-005979SEC(opens sec.gov)
Companies
- Adynxx, Inc.Director
- ARMO BioSciences, Inc.Director
- BICYCLE THERAPEUTICS PLCDirectorBCYC
- Forest Laboratories, LLCDirector
- NephroGenex, Inc.Director, Chief Executive Officer
- NEW RITE AID, LLCSenior Executive VP
- NPS PHARMACEUTICALS INCDirector
- OSI PHARMACEUTICALS INCExec. VP, CFO & Treasurer
- Syndax Pharmaceuticals IncDirectorSNDX
- Tobira Therapeutics, Inc.Director
- Urovant Sciences Ltd.Director
Address
C/O SYNDAX PHARMACEUTICALS, INC. 730 THIRD AVENUE, FLOOR 9
NEW YORK, NY, 10017